NVIDIA's BioNeMo platform has signed partnerships with Thermo Fisher and Eli Lilly, establishing it as the primary AI infrastructure for pharmaceutical research and development.1
Independent validation is following. Terray Therapeutics and Apheris have released their own models built on BioNeMo, signaling adoption beyond the platform's anchor partners.1
Novo Nordisk shares rose 24.9% over 30 days on strong Q1 2026 earnings, providing financial cover for a strategic restructuring.1 The Danish drugmaker licensed its Parkinson's cell therapy program to Cellular Intelligence, an AI-native partner, and shut down its internal cell therapy unit entirely.1
The move reflects a pattern taking hold across big pharma: outsource experimental modalities to AI-enabled specialists rather than build internal capability. Cellular Intelligence inherits a program with commercial potential while Novo Nordisk doubles down on its core GLP-1 franchise.
Foundation model activity is accelerating on multiple fronts. Natera, Basecamp Research with its EDEN platform, Boltz Lab, Owkin with OwkinZero, and Edison with Kosmos have each launched competing platforms in recent months.1 The proliferation marks a transition from an infrastructure-scarce environment to one where differentiation must come from biology, data, and clinical outcomes.
BioNeMo's advantage is its position at the intersection of compute and biomedical data pipelines. Thermo Fisher's experimental infrastructure and Eli Lilly's drug development scale give NVIDIA direct access to proprietary biological datasets — the fuel that separates production-grade AI from research demos.
The overall trajectory is bullish and improving. Confidence in AI drug discovery's commercial payoff is no longer speculative; it is being priced into pharma earnings and embedded into R&D strategy at the largest companies in the sector.
The question is no longer whether AI will transform drug discovery. It is which platforms will own the stack when the first AI-native approvals land.